Select Page

From Breeding to a Full Service CRO

13 years of driving innovation and impact in preclinical research

Our Story

Foundation & Early Focus.

InnoSer started as a mouse model breeding facility which has been the backbone of our services and started a vision for a better way to support researchers. A decade later, that vision has grown into a trusted preclinical CRO, helping to advance breakthrough science across multiple therapeutic areas.

Our name, a simple fusion of Innovative Services, reflects more than just what we offer, it’s how we think, evolve, and collaborate. We don’t just provide research solutions; we innovate alongside our clients, shaping studies with flexibility, scientific rigor, and a commitment to progress.

We grew from a local research animal breeding provider to a global research partner, continually redefining how we can better serve the scientific community.

2012

InnoSer was founded in Lelystad, the Netherlands, as a colony management and breeding facility, ensuring researchers had access to high-quality, well-maintained mouse models. 

2015

Expansion into facility management services with the opening of a new site in Leiden, strengthening InnoSer’s capacity to maintain and manage preclinical models.

2017

The first step toward becoming a preclinical CRO – exclusive licensing of Prof. Dorien Peters’ ADPKD in vivo model, establishing InnoSer’s nephrology research expertise. Which we still offer nearly 10 years later.

2019

Oncology and neuroscience capabilities were introduced with the opening of in-vitro labs in Belgium, driven by a PDXO grant supporting patient-derived tumor organoid research (PDXO models)

Our Story

Strategic Shift to Preclinical Research.

Our Story

Portfolio Diversification & Industry Expansion.

2021

The launch of Connected-Pathology, enhanced InnoSer’s ability to integrate digital pathology into preclinical research.

2023

Acquisition of Sylics, a Dutch neuroscience CRO, bringing validated models, behavioral expertise, and rare neurological disease capabilities.

2024

Expansion into cardiometabolic disease research through the Beta-Cell acquisition, adding specialized in-house expertise and validated models. 

2025

Further strengthening of neuroscience services with the remynd acquisition, integrating Alzheimer’s and Parkinson’s disease models. 

By combining expertise, adaptability, and scientific excellence, we go beyond being a CRO, we’re a trusted partner for your discoveries.

How it works

Collaborate with Experts

We support toxicology, PK/PD profiling, efficacy and safety studies across oncology, neuroscience, nephrology, cardiology, metabolic disease, and rare diseases. Our scientists work directly with you, providing expert consultation, study design support, and model co-validation to ensure reliable and meaningful results. From refining study approaches to advising on next steps, we’re your partner in advancing research.

    Flexible & Transparent Execution

    Your study is built on scientific rigor and guided by a dedicated study director. We provide;

    ✓ Real-time updates
    ✓ Quality-controlled workflows
    ✓ Adaptable study designs to match evolving research needs

    We also recognize that research evolves, and we accommodate study modifications when necessary adjusting protocols based on preliminary findings or shifting research needs. This flexible, partnership-driven approach allows us to support dynamic projects with customized solutions.

      Fast & Client-Focused

      Many of our partners choose to work with us time and time again, and we deeply value these lasting relationships. Your research benefits from our adaptability, consultative approach, and ability to execute studies with speed and precision.

      As a returning client, you’ll receive:

      ✓ Priority study slots to keep your research moving forward.
      ✓ Loyalty programs and referral benefits as a token of our appreciation.
      ✓ Continuous improvements driven by your feedback to enhance our services.

      We’re here to support your success today and in the long run.

        Seamless Data Access & Reporting

        Your data is shared through a secure online platform as soon as it becomes available, with in-life phase data access during the active study. The reporting process includes:

        1. Draft Report: An initial formatted version, highlighting key data.
        2. Final Report: A detailed document following client-specific and regulatory guidelines.

        ✓ You benefit from post-study consultations, helping your team interpret results and determine optimal next steps.

          Preclinical Platform to Optimize the Efficacy and Safety of Leads

          Models and Locations Overview

          InnoSer Diepenbeek Site - Bioville

          InnoSer Belgium

          • 300 m2 in vitro and 500 m2 SPF facilities​
          • Capacity for 14.000 mice
          • AAALAC accredited​ & ISO 9001 certified​
          • State-of-the-art imaging equipment​
          • Digital Pathology Services​
          • Automated Workflows
          • Proprietary LIS
          InnoSer Leiden Site

          InnoSer Netherlands

          • 20 m2 in vitro and 1.000 m2 SPF facilities
          • Capacity of 6.500 mice
          • AAALAC accredited​ & ISO 9001 certified
          • In-Vivo Neuroscience CRO​
          • Automated home-cage-based screening
          • Histology 

          Leadership

          Kris Motmans

          Kris Motmans, PhD, CEO

          “Our research supports critical advancements in oncology, neuroscience, nephrology, cardiology, metabolic disease, and rare diseases, helping accelerate drug development and improve study success rates”.

          Kris Motmans, PhD

          Chief Executive Officer

          Yanick Fanton, PhD, CSO

          “Every study is unique. We adapt study designs, offer real-time data access, and provide quick turnaround times to meet evolving research needs”.

          Yanick Fanton, PhD

          Chief Science Officer

          Robbert Otten

          Robbert Otten, COO

          “We anticipate challenges before they arise, ensuring study designs align with the latest scientific and regulatory standards while maintaining strict quality control”.

          Robbert Otten

          Chief Operating Officer

          preclinical oncology researcher imaging organoids

          Maarten Loos, PhD, Managing Director NL

          “We work side by side with researchers, offering expert consultation, co-validation of models, and seamless communication with dedicated study directors”.

          Maarten Loos, PhD

          Managing Director NL

          Expertise

          Laura Blockken

          Laura Blockken

          Principal Scientist Nephrology

          Céline Erens, PhD

          Céline Erens, PhD

          Principal Scientist Oncology & Immunology

          Sofie Carmans, PhD

          Sofie Carmans, PhD

          Principal Scientist Neurology

          Thomas Vogels, PhD

          Thomas Vogels, PhD

          Principal Scientist Neurology

          Your Career Starts with InnoSer.

          No global movement springs from individuals. It takes an entire team united behind something big. Together we work hard, we laugh a lot and we put our minds together to provide proactive solutions for our clients. We are eager to make a difference

          Stay Curious: More Articles to Explore